Search Results - "Staley, Joshua M" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

by Yoder, Rachel, Kimler, Bruce F., Staley, Joshua M., Schwensen, Kelsey, Wang, Yen Y., Finke, Karissa, O’Dea, Anne, Nye, Lauren, Elia, Manana, Crane, Gregory, McKittrick, Richard, Pluenneke, Robert, Madhusudhana, Sheshadri, Beck, Larry, Shrestha, Anuj, Corum, Larry, Marsico, Mark, Stecklein, Shane R., Godwin, Andrew K., Khan, Qamar J., Sharma, Priyanka
Published in NPJ breast cancer (11.07.2022)

Get full text

Journal Article

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

by Stecklein, Shane R., Kimler, Bruce F., Yoder, Rachel, Schwensen, Kelsey, Staley, Joshua M., Khan, Qamar J., O’Dea, Anne P., Nye, Lauren E., Elia, Manana, Heldstab, Jaimie, Home, Trisha, Hyter, Stephen, Isakova, Kamilla, Pathak, Harsh B., Godwin, Andrew K., Sharma, Priyanka
Published in NPJ breast cancer (06.03.2023)

Get full text

Journal Article

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)

by Sharma, Priyanka, Kimler, Bruce F, O'Dea, Anne, Nye, Lauren, Wang, Yen Y, Yoder, Rachel, Staley, Joshua M, Prochaska, Lindsey, Wagner, Jamie, Amin, Amanda L, Larson, Kelsey, Balanoff, Christa, Elia, Manana, Crane, Gregory, Madhusudhana, Sheshadri, Hoffmann, Marc, Sheehan, Maureen, Rodriguez, Roberto, Finke, Karissa, Shah, Rajvi, Satelli, Deepti, Shrestha, Anuj, Beck, Larry, McKittrick, Richard, Pluenneke, Robert, Raja, Vinay, Beeki, Venkatadri, Corum, Larry, Heldstab, Jaimie, LaFaver, Stephanie, Prager, Micki, Phadnis, Milind, Mudaranthakam, Dinesh Pal, Jensen, Roy A, Godwin, Andrew K, Salgado, Roberto, Mehta, Kathan, Khan, Qamar
Published in Clinical cancer research (15.02.2021)

Get full text

Journal Article

Extinction of chromosomes due to specialization is a universal occurrence

Extinction of chromosomes due to specialization is a universal occurrence

by Wilson, Jason, Staley, Joshua M., Wyckoff, Gerald J.
Published in Scientific reports (07.02.2020)

Get full text

Journal Article

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

by Martín, Miguel, Yoder, Rachel, Salgado, Roberto, Del Monte-Millán, María, Álvarez, Enrique L, Echavarría, Isabel, Staley, Joshua M, O'Dea, Anne P, Nye, Lauren E, Stecklein, Shane R, Bueno, Coralia, Jerez, Yolanda, Cebollero, María, Bueno, Oscar, García Saenz, José Ángel, Moreno, Fernando, Bohn, Uriel, Gómez, Henry, Massarrah, Tatiana, Khan, Qamar J, Godwin, Andrew K, López-Tarruella, Sara, Sharma, Priyanka
Published in Clinical cancer research (15.05.2024)

Get full text

Journal Article

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial

by Sharma, Priyanka, Stecklein, Shane R, Yoder, Rachel, Staley, Joshua M, Schwensen, Kelsey, O'Dea, Anne, Nye, Lauren, Satelli, Deepti, Crane, Gregory, Madan, Rashna, O'Neil, Maura F, Wagner, Jamie, Larson, Kelsey E, Balanoff, Christa, Kilgore, Lyndsey, Phadnis, Milind A, Godwin, Andrew K, Salgado, Roberto, Khan, Qamar J, O'Shaughnessy, Joyce
Published in JAMA oncology (01.02.2024)

Get more information

Journal Article

Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial

Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial

by Stecklein, Shane R, Yoder, Rachel, Staley, Joshua M., Schmitt, Zachary, O'Dea, Anne, Nye, Lauren Elizabeth, Elia, Manana, Satelli, Deepti, Crane, Gregory James, Madan, Rashna, O'Neil, Maura F., Godwin, Andrew K., Salgado, Roberto, Khan, Qamar J., O'Shaughnessy, Joyce, Sharma, Priyanka
Published in Journal of clinical oncology (01.06.2023)

Get full text

Journal Article

NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC)

NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC)

by Stecklein, Shane R., Aripoli, Allison, Salgado, Roberto, O'Dea, Anne, Nye, Lauren Elizabeth, Larson, Kelsey E., Satelli, Deepti, Rader, Ryan, Madan, Rashna, Yoder, Rachel, Staley, Joshua M., Fernandez, India, Heinrich, Adam, Wagner, Jamie L., Balanoff, Christa, Kilgore, Lyndsey, Bantis, Leonidas, Godwin, Andrew K., Khan, Qamar J., Sharma, Priyanka
Published in Journal of clinical oncology (01.06.2024)

Get full text

Journal Article

Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease

Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease

by Sharma, Priyanka, Stecklein, Shane R, Kimler, Bruce F, Yoder, Rachel, Schwensen, Kelsey, Staley, Joshua M, Khan, Qamar J, O'Dea, Anne P, Nye, Lauren E, Elia, Manana, Heldstab, Jaimie, Home, Trisha, Hyter, Stephen, Isakova, Kamilla, Pathak, Harsh B, Godwin, Andrew K
Published in Cancer research (Chicago, Ill.) (15.02.2022)

Get full text

Journal Article

Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD)

Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD)

by Stecklein, Shane R, Koestler, Devin, Yellapu, Nanda K, Yoder, Rachel, Kimler, Bruce F., Staley, Joshua M., Schmitt, Zachary, Khan, Qamar J., O'Dea, Anne, Nye, Lauren Elizabeth, Elia, Manana, Heldstab, Jaimie, Home, Trisha, Hyter, Stephen, Isakova, Kamilla, Pathak, Harsh B, Godwin, Andrew K., Sharma, Priyanka
Published in Journal of clinical oncology (01.06.2023)

Get full text

Journal Article

Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT)

Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT)

by Sharma, Priyanka, Stecklein, Shane Richard, Yoder, Rachel, Staley, Joshua M., Schwensen, Kelsey, O'Dea, Anne, Nye, Lauren Elizabeth, Elia, Manana, Satelli, Deepti, Crane, Gregory, Madan, Rashna, O'Neil, Maura F., Wagner, Jamie L., Larson, Kelsey E., Balanoff, Christa, Phadnis, Milind A., Godwin, Andrew K., Salgado, Roberto, Khan, Qamar J., O'Shaughnessy, Joyce
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC)

Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC)

by Sharma, Priyanka, Abramson, Vandana G, O'Dea, Anne, Nye, Lauren Elizabeth, Mayer, Ingrid A., Crane, Gregory James, Elia, Manana, Yoder, Rachel, Staley, Joshua M, Schwensen, Kelsey, Finke, Karissa, Heldstab, Jaimie, LaFaver, Stephanie, Prager, Micki, Williamson, Stephen K., Phadnis, Milind, Reed, Gregory A, Kimler, Bruce F., Khan, Qamar J., Godwin, Andrew K.
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

Abstract PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer

Abstract PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer

by Yoder, Rachel, Kimler, Bruce F, Staley, Joshua M, Schwensen, Kelsey, Wang, Yen Y, Finke, Karissa, O'Dea, Anne, Nye, Lauren, Elia, Manana, Crane, Gregory, McKittrick, Richard, Pluenneke, Robert, Madhusudhana, Sheshadri, Beck, Larry, Rodriguez, Roberto, Shrestha, Anuj, Corum, Larry, Marsico, Mark, Godwin, Andrew K, Khan, Qamar, Sharma, Priyanka
Published in Cancer research (Chicago, Ill.) (15.02.2021)

Get full text

Journal Article

Abstract 5215: Orphan noncoding RNA (oncRNA) liquid biopsy assay is prognostic for survival in patients with triple-negative breast cancer (TNBC) and residual disease

Abstract 5215: Orphan noncoding RNA (oncRNA) liquid biopsy assay is prognostic for survival in patients with triple-negative breast cancer (TNBC) and residual disease

by Yoder, Rachel, Yen, Jennifer, Karimzadeh, Mehran, Staley, Joshua M., Fernandez, India, Heinrich, Adam C., Hormozdiari, Fereydoun, Gregg, Jeffrey, Godwin, Andrew K., Acerbi, Irene, Trivedi, Raaj, Alipanahi, Babak, Stecklein, Shane R., Sharma, Priyanka
Published in Cancer research (Chicago, Ill.) (22.03.2024)

Get full text

Journal Article

Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials

Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials

by Sharma, Priyanka, Stecklein, Shane R., Yoder, Rachel, Staley, Joshua M., Salgado, Roberto, Paré, Laia, Conte, Benedetta, Brasó-Maristany, Fara, O’Dea, Anne, Nye, Lauren, Elia, Manana, Satelli, Deepti, Crane, Gregory, McKittrick, Richard, Khan, Qamar, Godwin, Andrew K., Prat, Aleix
Published in Cancer research (Chicago, Ill.) (01.03.2023)

Get full text

Journal Article

Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy

Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy

by Stecklein, Shane R., Yoder, Rachel, Salgado, Roberto, Staley, Joshua M., O’Dea, Anne, Nye, Lauren, Elia, Manana, Satelli, Deepti, Crane, Gregory, McKittrick, Richard, Godwin, Andrew K., Khan, Qamar, Sharma, Priyanka
Published in Cancer research (Chicago, Ill.) (01.03.2023)

Get full text

Journal Article